Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b

Heinz L. Seewann , Ronald Zikulnig , Gertraud Gallhofer , Christine Schmid
{"title":"Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b","authors":"Heinz L. Seewann ,&nbsp;Ronald Zikulnig ,&nbsp;Gertraud Gallhofer ,&nbsp;Christine Schmid","doi":"10.1016/0277-5379(91)90576-Y","DOIUrl":null,"url":null,"abstract":"<div><p>Thirty-six patients with chronic myeloproliferative disorders (CMPD) with thrombocytosis (essential thrombocythaemia 19 patients, chronic megakaryocytic granulocytic myelosis five, polycythaemia vera six, chronic myelogenous leukaemia six) were treated with interferon alfa-2b to reduce the platelet count. The pre-treatment platelet count was in the range 450–700 × 10<sup>9</sup>/L in eight patients, 700–1000 × 10<sup>9</sup>/L in eight and above 1000 × 10<sup>9</sup>/L in 20. In the induction phase of treatment 22 patients were treated with interferon alfa-2b 3 million units (MU) daily subcutaneously for 2 months or until the platelet count returned to normal, if earlier. Fourteen patients received 5 MU interferon alfa-2b daily in the same way. In the maintenance phase the doses were reduced to 3 MU and 5 MU thrice weekly, respectively. Complete response (CR), defined as a reduction of platelet count to below 450 × 10<sup>9</sup>/L, was achieved in 78% of patients (within 2 months of induction in 64%). The platelet depleting effect was dose dependent: CR in 2 months in 52% on 3 MU interferon alfa-2b versus 75% on 5 MU. Reduction of interferon dose was followed by an increase in platelet count in 39% of patients. The white cell count fell by 50% in Philadelphia-negative CMPD. Side effects were common, though generally mild, but led to withdrawal of treatment in six patients. Three patients suffered cerebrovascular events during treatment and one shortly thereafter.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90576-Y","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190576Y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

Thirty-six patients with chronic myeloproliferative disorders (CMPD) with thrombocytosis (essential thrombocythaemia 19 patients, chronic megakaryocytic granulocytic myelosis five, polycythaemia vera six, chronic myelogenous leukaemia six) were treated with interferon alfa-2b to reduce the platelet count. The pre-treatment platelet count was in the range 450–700 × 109/L in eight patients, 700–1000 × 109/L in eight and above 1000 × 109/L in 20. In the induction phase of treatment 22 patients were treated with interferon alfa-2b 3 million units (MU) daily subcutaneously for 2 months or until the platelet count returned to normal, if earlier. Fourteen patients received 5 MU interferon alfa-2b daily in the same way. In the maintenance phase the doses were reduced to 3 MU and 5 MU thrice weekly, respectively. Complete response (CR), defined as a reduction of platelet count to below 450 × 109/L, was achieved in 78% of patients (within 2 months of induction in 64%). The platelet depleting effect was dose dependent: CR in 2 months in 52% on 3 MU interferon alfa-2b versus 75% on 5 MU. Reduction of interferon dose was followed by an increase in platelet count in 39% of patients. The white cell count fell by 50% in Philadelphia-negative CMPD. Side effects were common, though generally mild, but led to withdrawal of treatment in six patients. Three patients suffered cerebrovascular events during treatment and one shortly thereafter.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
干扰素α -2b治疗慢性骨髓增生性疾病的血小板增多症
对36例合并血小板增多的慢性骨髓增生疾病(CMPD)患者(原发性血小板增多症19例,慢性巨核粒细胞性骨髓增生症5例,真性红细胞增多症6例,慢性粒细胞性白血病6例)进行干扰素α -2b治疗,以降低血小板计数。治疗前血小板计数450 ~ 700 × 109/L 8例,700 ~ 1000 × 109/L 8例,1000 × 109/L以上20例。在诱导治疗阶段,22例患者每天皮下注射300万单位(MU)干扰素α -2b治疗2个月或直到血小板计数恢复正常(如果更早)。14例患者每日以相同方式给予5 μ干扰素α -2b。在维持期,剂量分别减少到3 MU和5 MU,每周3次。78%的患者达到完全缓解(CR),定义为血小板计数降至450 × 109/L以下(64%的患者在诱导后2个月内)。血小板消耗作用是剂量依赖性的:干扰素α -2b组2个月CR为3mu组52%,而干扰素α -2b组为5mu组75%。干扰素剂量减少后,39%的患者血小板计数增加。费城CMPD阴性患者白细胞计数下降50%。副作用是常见的,虽然通常轻微,但导致6名患者退出治疗。3名患者在治疗期间发生脑血管事件,1名患者在治疗后不久发生脑血管事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Preclinical evaluation of polymer-bound doxorubicin Corrections News Introduction Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1